Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, Sweden.
BMJ Open. 2022 Jun 8;12(6):e062172. doi: 10.1136/bmjopen-2022-062172.
To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT).
Retrospective analysis of serial cross-sectional screening study.
Population-based health examinations within primary care in Västerbotten County, Sweden.
Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded.
Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9-12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses.
The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined.
The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population.
评估口服葡萄糖耐量试验(OGTT)联合空腹血糖(FPG)检测对 2 型糖尿病(T2D)和糖耐量受损(IGT)的影响。
基于人群的初级保健中连续横断面筛查研究的回顾性分析。
瑞典韦斯特博滕县。
年龄在 40-50 岁和 60 岁之间的个体,1985 年至 2017 年参与其中。已诊断患有糖尿病和 FPG≥7mmol/L 的个体被排除在外。
OGTT 后高血糖的患病率(IGT 和 T2D 定义为 2 小时毛细血管血浆葡萄糖 8.9-12.1mmol/L 和≥12.2mmol/L)。进一步按年龄、性别和危险因素负担进行分层分析,以确定在检测时处于 IGT 和 T2D 高风险或低风险的人群。根据以前的荟萃分析中患病率数据与平均进展率和干预效果相结合,估计通过检测和治疗 IGT 来预防一例 T2D 所需的筛查人数(NNS)。
IGT 的患病率从 0.9%(95%CI0.7%至 1.1%)到 29.6%(95%CI27.4%至 31.7%)不等,T2D 的患病率从 0.06%(95%CI0.02%至 0.11%)到 7.0%(95%CI5.9%至 8.3%)不等,这强烈取决于年龄、性别和危险因素负担。通过检测和生活方式治疗 IGT 预防一例 T2D 所需的估计 NNS 从无危险因素的 40 岁男性中的 1332 例到所有危险因素合并的 60 岁女性中的 39 例不等。
OGTT 后高血糖的患病率高度依赖于年龄、性别和危险因素负担;OGTT 应选择性地应用于高危人群,以避免在一般人群中进行不必要的检测。